APIM Therapeutics
Trondheim
About APIM Therapeutics
APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellular responses to DNA damage and stress.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $3.0M
- Last round: Series Unknown (Dec 2017)
- Website: apimtherapeutics.com
- Phone: +47 73 49 4002
Industries & Categories
Biotechnology, Finance, Therapeutics, Venture Capital
Social Profiles
Canonical: https://fsome.com/organization/apim-therapeutics-145492 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.